



October 21, 2015

Dear CRU investigators,

The National Center for Advancing Translational Sciences (NCATS) of NIH, which supports the ICTR Clinical Research Units (CRUs) through its CTSA program, announced last year that direct support of CRUs will not be allowed for any new or re-competing CTSA awards. Our CRUs have been a major source of support for investigators throughout Johns Hopkins and this change in policy will have a significant impact on our future ICTR operations. This NCATS policy has already been implemented for the 18 CTSA "Hubs" that received a new award this year and we have been informed that the policy will remain in effect for our next CTSA competing renewal (expected in May of 2018).

Consequently, in May, 2018, our CRUs will begin to operate using a service center model; therefore, CRU charges will need to be included in budgets for all future grant applications that request these services.

In order to help you plan for the future, we have developed the attached list of charges for CRU space and services, including the Johns Hopkins Hospital and Bayview campuses, and the PCRU. We recommend that you use this charge list to develop budgets for current and future NIH and foundation grant applications. The CRU charges for industry-sponsored studies will remain unchanged. We have been told that all NIH institutes and centers have been informed of this change in NCATS policy regarding the CTSA's, and should expect to see these costs reflected in future grant budgets.

For investigators with active grants that anticipated continued CRU support beyond May, 2018, we recommend that you contact your sponsor or NIH Program Official to discuss needs for supplemental funding in future years to cover CRU costs.

We want to thank you for being a loyal supporter of the ICTR Clinical Research Units, and an advocate for the value they add to your human subjects research. Certainly, if you have questions about this change, or the attached charges, please do not hesitate to contact us for clarification.

Sincerely,

A handwritten signature in blue ink, appearing to read "Mark R. Garcia".

Mark R. Garcia  
Administrator, ICTR

A handwritten signature in blue ink, appearing to read "Charles W. Flexner".

Charles W. Flexner, MD  
Program Director, ICTR CRUs

A handwritten signature in blue ink, appearing to read "Daniel E. Ford".

Daniel E. Ford, MD, MPH  
Director, ICTR